161 related articles for article (PubMed ID: 18663147)
1. Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia.
Cheng CK; Li L; Cheng SH; Lau KM; Chan NP; Wong RS; Shing MM; Li CK; Ng MH
Blood; 2008 Oct; 112(8):3391-402. PubMed ID: 18663147
[TBL] [Abstract][Full Text] [Related]
2. Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia.
Zhao Y; Zhang T; Zhao Y; Zhou J
Cancer Biomark; 2020; 29(3):387-397. PubMed ID: 32741803
[TBL] [Abstract][Full Text] [Related]
3. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
5. RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Estécio MR; Maddipoti S; Bueso-Ramos C; DiNardo CD; Yang H; Wei Y; Kondo K; Fang Z; Stevenson W; Chang KS; Pierce SA; Bohannan Z; Borthakur G; Kantarjian H; Garcia-Manero G
Br J Haematol; 2015 May; 169(3):344-51. PubMed ID: 25612675
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
[TBL] [Abstract][Full Text] [Related]
7. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
Marcucci G; Caligiuri MA; Bloomfield CD
Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
[TBL] [Abstract][Full Text] [Related]
8. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
10. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of RUNX3 inhibits normal human myeloid development.
Menezes AC; Jones R; Shrestha A; Nicholson R; Leckenby A; Azevedo A; Davies S; Baker S; Gilkes AF; Darley RL; Tonks A
Leukemia; 2022 Jul; 36(7):1769-1780. PubMed ID: 35490198
[TBL] [Abstract][Full Text] [Related]
12. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
13. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
[TBL] [Abstract][Full Text] [Related]
14. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.
Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH
Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588
[TBL] [Abstract][Full Text] [Related]
15. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1.
Ben-Ami O; Friedman D; Leshkowitz D; Goldenberg D; Orlovsky K; Pencovich N; Lotem J; Tanay A; Groner Y
Cell Rep; 2013 Sep; 4(6):1131-43. PubMed ID: 24055056
[TBL] [Abstract][Full Text] [Related]
16. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
17. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
18. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
19. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
20. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
